Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations

Non-small-cell lung cancer (NSCLC) is the primary cause of cancer-related death. Gene rearrangements involving the anaplastic lymphoma kinase (ALK) tyrosine kinase identify a clinical and molecular subset of NSCLC patients, who benefit from the monotherapy with ALK tyrosine kinase inhibitors. Noneth...

詳細記述

書誌詳細

出版年:	Translational Oncology
主要な著者:	Matteo Canale, Elisabetta Petracci, Paola Cravero, Marita Mariotti, Gabriele Minuti, Giulio Metro, Vienna Ludovini, Sara Baglivo, Maurizio Puccetti, Alessandra Dubini, Giovanni Martinelli, Angelo Delmonte, Lucio Crinò, Paola Ulivi
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2022-09-01
主題:	Non-small cell lung cancer (NSCLC) Anaplastic lymphoma kinase (ALK) gene re-arrangements Tumor protein 53 (TP53) gene mutations Prognosis Therapy resistance
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1936523322001309